164 related articles for article (PubMed ID: 37982809)
1. Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma.
Nabavizadeh A; Bagley SJ
Clin Cancer Res; 2024 Jan; 30(2):255-256. PubMed ID: 37982809
[TBL] [Abstract][Full Text] [Related]
2. O
Schoenfeld JD; Sibenaller ZA; Mapuskar KA; Wagner BA; Cramer-Morales KL; Furqan M; Sandhu S; Carlisle TL; Smith MC; Abu Hejleh T; Berg DJ; Zhang J; Keech J; Parekh KR; Bhatia S; Monga V; Bodeker KL; Ahmann L; Vollstedt S; Brown H; Shanahan Kauffman EP; Schall ME; Hohl RJ; Clamon GH; Greenlee JD; Howard MA; Schultz MK; Smith BJ; Riley DP; Domann FE; Cullen JJ; Buettner GR; Buatti JM; Spitz DR; Allen BG
Cancer Cell; 2017 Apr; 31(4):487-500.e8. PubMed ID: 28366679
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
4. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
[TBL] [Abstract][Full Text] [Related]
6. Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.
Suwala AK; Hanaford A; Kahlert UD; Maciaczyk J
J Neuropathol Exp Neurol; 2016 May; 75(5):388-96. PubMed ID: 26979081
[TBL] [Abstract][Full Text] [Related]
7. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
8. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
9. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.
Gray GK; McFarland BC; Nozell SE; Benveniste EN
Expert Rev Neurother; 2014 Nov; 14(11):1293-306. PubMed ID: 25262780
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic targets and agents for glioblastoma therapy - part I.
Lo HW
Anticancer Agents Med Chem; 2010 Jul; 10(6):437. PubMed ID: 20937018
[No Abstract] [Full Text] [Related]
11. Emerging therapeutic targets and agents for glioblastoma therapy--part II.
Lo HW
Anticancer Agents Med Chem; 2010 Sep; 10(7):511. PubMed ID: 21070189
[No Abstract] [Full Text] [Related]
12. Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.
Petronek MS; Monga V; Bodeker KL; Kwofie M; Lee CY; Mapuskar KA; Stolwijk JM; Zaher A; Wagner BA; Smith MC; Vollstedt S; Brown H; Chandler ML; Lorack AC; Wulfekuhle JS; Sarkaria JN; Flynn RT; Greenlee JDW; Howard MA; Smith BJ; Jones KA; Buettner GR; Cullen JJ; St-Aubin J; Buatti JM; Magnotta VA; Spitz DR; Allen BG
Clin Cancer Res; 2024 Jan; 30(2):283-293. PubMed ID: 37773633
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
14. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
16. Overcoming TRAIL Resistance for Glioblastoma Treatment.
Deng L; Zhai X; Liang P; Cui H
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
[TBL] [Abstract][Full Text] [Related]
18. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
19. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
